Insider · CIK 0001902368

Inrig Jula

Reports to the SEC for 1 company · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001902368

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-15	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	EVP, Head of R&D & CMO	MExercise/Conversion	+32.4K sh	$8.93	+$289K	145,165
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−25.4K sh	$62.02	−$1.57M	119,775
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−17.3K sh	$62.62	−$1.08M	102,491
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−1,600 sh	$63.69	−$102K	100,891
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−400 sh	$65.31	−$26.1K	100,491
2026-09-15	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	EVP, Head of R&D & CMO	MExercise/Conversion	−32.4K sh	—	—	43,605
2026-06-22	TVTXTravere Therapeutics, Inc.G Gift	EVP, Head of R&D & CMO	GGift	−468 sh	—	—	112,770
2026-05-06	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−311 sh	$43.95	−$13.7K	113,238
2026-05-05	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−2,174 sh	$46.65	−$101K	113,549
2026-05-04	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	EVP, Head of R&D & CMO	MExercise/Conversion	+20K sh	$22.40	+$448K	131,473
2026-05-04	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−20K sh	$45.00	−$900K	111,473
2026-05-04	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	EVP, Head of R&D & CMO	MExercise/Conversion	+4,250 sh	—	—	115,723
2026-05-04	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	EVP, Head of R&D & CMO	MExercise/Conversion	−20K sh	—	—	34,500
2026-05-04	TVTXTravere Therapeutics, Inc. · Performance-based restricted stock unitsA Award	EVP, Head of R&D & CMO	AAward	+8,500 sh	—	—	8,500
2026-05-04	TVTXTravere Therapeutics, Inc. · Performance-based restricted stock unitsM Exercise/Conversion	EVP, Head of R&D & CMO	MExercise/Conversion	−4,250 sh	—	—	4,250
2026-04-15	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−1,018 sh	$42.61	−$43.4K	111,473
2026-04-14	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−7,215 sh	$41.93	−$303K	112,491
2026-04-13	TVTXTravere Therapeutics, Inc.A Award	EVP, Head of R&D & CMO	AAward	+14K sh	—	—	119,706
2026-02-04	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−1,547 sh	$32.11	−$49.7K	105,938
2026-02-04	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−232 sh	$32.85	−$7,621.2	105,706
2026-02-03	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−6,956 sh	$32.12	−$223K	107,485
2026-01-31	TVTXTravere Therapeutics, Inc.A Award	EVP, Head of R&D & CMO	AAward	+28.1K sh	—	—	114,441
2026-01-31	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)A Award	EVP, Head of R&D & CMO	AAward	+75K sh	—	—	75,000
2026-01-06	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−445 sh	$37.75	−$16.8K	86,311
2026-01-05	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−2,031 sh	$40.18	−$81.6K	86,756
2025-12-24	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	EVP, Head of R&D & CMO	MExercise/Conversion	+15K sh	$8.93	+$134K	103,787
2025-12-24	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−15K sh	$42.00	−$630K	88,787
2025-12-24	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	EVP, Head of R&D & CMO	MExercise/Conversion	−15K sh	—	—	76,000
2025-07-01	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−815 sh	$14.65	−$11.9K	88,787
2025-02-12	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−2,568 sh	$23.53	−$60.4K	89,602
2025-02-10	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	EVP, Head of R&D & CMO	MExercise/Conversion	+8,000 sh	—	—	92,170
2025-02-10	TVTXTravere Therapeutics, Inc. · Performance-based restricted stock unitsM Exercise/Conversion	EVP, Head of R&D & CMO	MExercise/Conversion	−8,000 sh	—	—	0
2025-02-04	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−1,066 sh	$20.11	−$21.4K	84,170
2025-02-03	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−4,207 sh	$20.12	−$84.6K	85,236
2025-01-31	TVTXTravere Therapeutics, Inc.A Award	EVP, Head of R&D & CMO	AAward	+30K sh	—	—	89,443
2025-01-31	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)A Award	EVP, Head of R&D & CMO	AAward	+100K sh	—	—	100,000
2025-01-06	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−440 sh	$18.76	−$8,254.4	59,443
2025-01-03	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−2,066 sh	$19.10	−$39.5K	59,883
2024-09-10	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−684 sh	$12.98	−$8,878.32	61,949
2024-09-09	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−2,191 sh	$11.52	−$25.2K	62,633
2024-09-05	TVTXTravere Therapeutics, Inc.A Award	EVP, Head of R&D & CMO	AAward	+6,750 sh	—	—	64,824
2024-02-01	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−2,174 sh	$8.53	−$18.5K	58,074
2024-01-31	TVTXTravere Therapeutics, Inc.A Award	EVP, Head of R&D & CMO	AAward	+25K sh	—	—	60,248
2024-01-31	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)A Award	EVP, Head of R&D & CMO	AAward	+91K sh	—	—	91,000
2024-01-04	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−440 sh	$9.17	−$4,034.8	35,248
2024-01-03	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−2,069 sh	$9.48	−$19.6K	35,688
2023-01-31	TVTXTravere Therapeutics, Inc.A Award	EVP, Head of R&D & CMO	AAward	+20.3K sh	—	—	37,757
2023-01-31	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)A Award	EVP, Head of R&D & CMO	AAward	+54.5K sh	—	—	54,500
2023-01-31	TVTXTravere Therapeutics, Inc. · Performance-based restricted stock unitsA Award	EVP, Head of R&D & CMO	AAward	+6,750 sh	—	—	6,750
2023-01-05	TVTXTravere Therapeutics, Inc.S Sale	EVP, Head of R&D & CMO	SSale	−442 sh	$20.75	−$9,171.5	17,507

Recent filings

Accepted (ET)
Sep 174
Inrig Jula0001902368-26-000008
SEC(opens sec.gov)
Jun 224
Inrig Jula0001902368-26-000007
SEC(opens sec.gov)
May 64
Inrig Jula0001902368-26-000006
SEC(opens sec.gov)
Apr 154
Inrig Jula0001902368-26-000005
SEC(opens sec.gov)
Feb 54
Inrig Jula0001902368-26-000004
SEC(opens sec.gov)

Companies

Travere Therapeutics, Inc.EVP, Head of R&D & CMOTVTX

Address

C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DRIVE, SUITE 300

SAN DIEGO, CA, 92130